📊 HOTH Key Takeaways
Is Hoth Therapeutics, Inc. (HOTH) a Good Investment?
Hoth Therapeutics is operationally unprofitable with negative cash burn of $3.1M annually and limited cash runway of approximately 1.3 years. Despite strong liquidity ratios and zero debt, the company shows deteriorating financial health with negative ROE/ROA and must achieve profitability or secure additional funding to survive.
Hoth Therapeutics shows persistent operating and net losses with extremely negative ROE/ROA and material cash burn relative to a small asset base. While the balance sheet is debt-free and liquidity is strong (cash exceeds total liabilities), the burn rate suggests a short runway without fresh capital or a sustainable revenue base. Until profitability and operating cash flow trends improve, fundamentals remain unfavorable.
Why Buy Hoth Therapeutics, Inc. Stock? HOTH Key Strengths
- Strong cash position of $4.0M with zero long-term debt
- Excellent liquidity ratios (3.39x current ratio) providing short-term financial flexibility
- Minimal leverage reduces bankruptcy risk in the near term
- Debt-free capital structure
- Cash and equivalents exceed total liabilities
- High current/quick ratio supports near-term liquidity
HOTH Stock Risks: Hoth Therapeutics, Inc. Investment Risks
- Significant cash burn of $3.1M annually with limited runway before additional funding becomes critical
- Persistent operating losses and negative profitability with poor capital returns (ROE -64.7%, ROA -48.1%)
- Pharmaceutical sector execution risk with no demonstrated path to sustainable profitability
- Sustained operating and net losses with deeply negative ROE/ROA
- Short cash runway given sizable operating cash outflow
- Unclear revenue quality and gross margin (N/A), potential non-recurring revenue
Key Metrics to Watch
- Operating cash flow trajectory and quarterly cash burn rate trends
- Path to profitability and quarterly operating income improvements
- Revenue sustainability and evidence of gross margin expansion
- Operating cash flow (burn/runway)
- Cash & equivalents relative to burn
Hoth Therapeutics, Inc. (HOTH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.39x current ratio provides a solid financial cushion.
HOTH Profit Margin, ROE & Profitability Analysis
HOTH vs Healthcare Sector: How Hoth Therapeutics, Inc. Compares
How Hoth Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Hoth Therapeutics, Inc. Stock Overvalued? HOTH Valuation Analysis 2026
Based on fundamental analysis, Hoth Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Hoth Therapeutics, Inc. Balance Sheet: HOTH Debt, Cash & Liquidity
HOTH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Hoth Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.28 indicates the company is currently unprofitable.
HOTH Revenue Growth, EPS Growth & YoY Performance
HOTH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $1.2B | -$1.6M | $-0.31 |
| Q2 2024 | $1.2B | -$1.6M | $-0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Hoth Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
HOTH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Hoth Therapeutics, Inc. (CIK: 0001711786)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HOTH
What is the AI rating for HOTH?
Hoth Therapeutics, Inc. (HOTH) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 62% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are HOTH's key strengths?
Claude: Strong cash position of $4.0M with zero long-term debt. Excellent liquidity ratios (3.39x current ratio) providing short-term financial flexibility. ChatGPT: Debt-free capital structure. Cash and equivalents exceed total liabilities.
What are the risks of investing in HOTH?
Claude: Significant cash burn of $3.1M annually with limited runway before additional funding becomes critical. Persistent operating losses and negative profitability with poor capital returns (ROE -64.7%, ROA -48.1%). ChatGPT: Sustained operating and net losses with deeply negative ROE/ROA. Short cash runway given sizable operating cash outflow.
What is HOTH's revenue and growth?
Hoth Therapeutics, Inc. reported revenue of $1.2B.
Does HOTH pay dividends?
Hoth Therapeutics, Inc. does not currently pay dividends.
Where can I find HOTH SEC filings?
Official SEC filings for Hoth Therapeutics, Inc. (CIK: 0001711786) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HOTH's EPS?
Hoth Therapeutics, Inc. has a diluted EPS of $-0.17.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HOTH a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Hoth Therapeutics, Inc. has a SELL rating with 62% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is HOTH stock overvalued or undervalued?
Valuation metrics for HOTH: ROE of -64.7% (sector avg: 15%), net margin of -0.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy HOTH stock in 2026?
Our dual AI analysis gives Hoth Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HOTH's free cash flow?
Hoth Therapeutics, Inc.'s operating cash flow is $-3.1M, with capital expenditures of $3.7K. FCF margin is -0.2%.
How does HOTH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -0.2% (avg: 12%), ROE -64.7% (avg: 15%), current ratio 3.39 (avg: 2).